 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...910111213141516171819...123124» |
- || Review, Journal, HEOR, Checkpoint inhibition, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review. (Pubmed Central) - Jul 5, 2024
The current evidence showed that ICIs, including atezolizumab plus bevacizumab, sintilimab plus bevacizumab/bevacizumab biosimilar, nivolumab, camrelizumab plus rivoceranib, pembrolizumab plus lenvatinib, tislelizumab, durvalumab, and cabozantinib plus atezolizumab, are probably not cost-effective in comparison with tyrosine kinase inhibitors or other ICIs...Our review demonstrated that ICIs were not a cost-effective intervention in advanced HCC. Although ICIs can significantly enhance the survival of patients with advanced HCC, decision-makers should consider the findings of economic evaluations and affordability before adoption of new therapies.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Postoperative Lenvatinib plus PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with MVI (BCLC 0-A): A Propensity Score Matching Analysis. (Pubmed Central) - Jul 4, 2024
Although ICIs can significantly enhance the survival of patients with advanced HCC, decision-makers should consider the findings of economic evaluations and affordability before adoption of new therapies. Postoperative lenvatinib +
- | Journal, Combination therapy, Checkpoint inhibition, Metastases: Prognostic Impact of the Administration of Antibiotics and Proton Pump Inhibitors in Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma. (Pubmed Central) - Jul 4, 2024
Antibiotics administration before ICI combination therapy was negatively associated with outcomes of first-line ICI combination therapy for advanced RCC. Therefore, careful monitoring is required for potentially high-risk patients undergoing ICI combination therapy.
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Enrollment closed, Trial initiation date, Metastases: Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 2, 2024
P2, N=50, Active, not recruiting, Sponsor: Asan Medical Center
Therefore, careful monitoring is required for potentially high-risk patients undergoing ICI combination therapy. Recruiting --> Active, not recruiting | Initiation date: Nov 2023 --> Jul 2023
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child-Pugh A category: A (Pubmed Central) - Jul 2, 2024
Recruiting --> Active, not recruiting | Initiation date: Nov 2023 --> Jul 2023 Lenvatinib RFA sequential therapy might offer favorable tolerability and potential prognostic improvement compared to lenvatinib monotherapy.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Retrospective data, Journal: Outcomes of hepatocellular carcinoma patients treated in the lenvatinib and immunotherapy era (2018-2021) compared to the sorafenib era (2008-2018). (Pubmed Central) - Jul 2, 2024
In this retrospective multicenter real-world study, HCC patients treated in the post-SOR era, where LEN and A?+?B were commonly used first-line treatments, exhibited superior OS, PFS, and RR compared to patients treated in the SOR era. The findings of this study affirm the tangible progress achieved in the real world in enhancing outcomes for HCC patients through advancements in treatments over the past 15?years.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, Journal, Metastases: Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. (Pubmed Central) - Jul 1, 2024
Lenvatinib plus pembrolizumab demonstrated antitumor activity as fourth line therapy in patients with advanced ovarian cancer, and no unanticipated safety signals were identified. Responses were observed regardless of PD-L1 status.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, Tumor microenvironment: Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment. (Pubmed Central) - Jul 1, 2024
The potent pan-FGFR/VEGFR inhibitor, Lenvatinib, uniformly induces tumor regression in AM patient-derived xenograft (PDX) tumors but only slows tumor growth in CM models...Considering the great difficulty in establishing AM cell culture lines, these findings suggest that AM may be more sensitive to microenvironment perturbations than CM. In conclusion, dual FGFR/VEGFR inhibition may be a viable therapeutic strategy that targets the unique biology of AM.
- | Journal, Metastases: Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma. (Pubmed Central) - Jul 1, 2024
Using more potent immuno-checkpoint inhibitors (ICIs), at least 4 phase III trials of adjuvant immunotherapy are ongoing: nivolumab, durvalumab/ bevacizumab, pembrolizumab, and atezolizumab+bevacizumab...There are 2 neoadjuvant trials for technically or oncologically unresectable HCCs ongoing in Japan: the LENS-HCC trial using lenvatinib and the RACB study using atezolizumab+bevacizumab...They obtained a Japanese consensus on this issue that has been published on the websites of JLCA and JSHPBS. The definition of resectability or borderline resectability provides a common language regarding advanced HCC for investigators and is a useful tool for future clinical trials.
- | New P2 trial, Metastases: Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer (clinicaltrials.gov) - Jun 30, 2024
P2, N=75, Recruiting, Sponsor: West China Hospital
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Expression of vascular endothelial growth factor receptor in thymic epithelial tumors. (Pubmed Central) - Jun 28, 2024
Lenvatinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, is approved as a drug therapy for thymic carcinoma (TC); however, although it is a molecular targeted therapy, there are no obvious predictors of therapeutic efficacy...Furthermore, the pathological stage was the only factor significantly associated with OS in multivariate analysis. The results of the present study suggest the possibility that the indications for VEGF inhibitor therapy could be extended to type B3 thymoma.
- || E7386 / Eisai, PRISM Pharma
Trial completion date, Trial primary completion date: KEYNOTE-C83: A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors (clinicaltrials.gov) - Jun 27, 2024
P1/2, N=89, Active, not recruiting, Sponsor: Eisai Inc.
The results of the present study suggest the possibility that the indications for VEGF inhibitor therapy could be extended to type B3 thymoma. Trial completion date: Sep 2025 --> Nov 2024 | Trial primary completion date: Sep 2025 --> Nov 2024
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open: QUILT 502: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (clinicaltrials.gov) - Jun 27, 2024
P1/2, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2025 --> Nov 2024 | Trial primary completion date: Sep 2025 --> Nov 2024 Suspended --> Recruiting
- || Review, Journal: The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review. (Pubmed Central) - Jun 27, 2024
Suspended --> Recruiting Our case, together with the systematic review, imply that a combination of molecular-targetedtreatments may be safe and effective in patients with RAI-resistantBRAF-mutated advanced PDTC when surgery has failed to control tumor progression.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Disease-Modifying Effects of Lenvatinib, a Multiple Receptor Tyrosine Kinase Inhibitor, on Posttraumatic Osteoarthritis of the Knee. (Pubmed Central) - Jun 27, 2024
Oral administration of lenvatinib inhibited synovitis, osteophyte formation, and cartilage degeneration and reduced pain in a rabbit ACLT model. Lenvatinib is an oral VEGF inhibitor that is easier to administer than other VEGF inhibitors and may have potential as a treatment of posttraumatic OA.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal: CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib. (Pubmed Central) - Jun 26, 2024
The CRAFITY score, utilizing C-reactive protein and alpha-fetoprotein values, emerges as a dependable and pragmatic instrument for forecasting the effectiveness of TACE plus lenvatinib in individuals with unresectable HCC. This scoring system holds the potential to assist oncologists in making informed clinical decisions.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker: Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. (Pubmed Central) - Jun 26, 2024
This scoring system holds the potential to assist oncologists in making informed clinical decisions. Combination lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-na
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial withdrawal: Neo PeLeMM: Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (clinicaltrials.gov) - Jun 25, 2024
P2, N=0, Withdrawn, Sponsor: Melanoma Institute Australia
Combination lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-na N=44 --> 0 | Not yet recruiting --> Withdrawn
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial completion date: PEMMELA: Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (clinicaltrials.gov) - Jun 25, 2024
P2, N=58, Active, not recruiting, Sponsor: The Netherlands Cancer Institute
N=44 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Mar 2025
- | Mekinist (trametinib) / Novartis, BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors (clinicaltrials.gov) - Jun 25, 2024
P2, N=100, Recruiting, Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Mar 2025 Trial completion date: Jan 2027 --> Jan 2037 | Trial primary completion date: Jan 2025 --> Jan 2029
- | Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Metastases: Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 24, 2024
P1, N=50, Recruiting, Sponsor: Zhiyong Huang
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal: The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study. (Pubmed Central) - Jun 22, 2024
PD-1 inhibitors did not improve the PFS and tumor response of unresectable HCC treated with TACE plus lenvatinib. Hepatitis B infection, liver cirrhosis, portal vein tumor thrombus, multiple tumors and large tumor diameter may be potential factors that affect the efficacy of PD-1 inhibitors but need further validation.
- |||| Trial completion date, Trial primary completion date, Metastases: MK-6482-012 China Extension: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study (clinicaltrials.gov) - Jun 21, 2024
P3, N=249, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Hepatitis B infection, liver cirrhosis, portal vein tumor thrombus, multiple tumors and large tumor diameter may be potential factors that affect the efficacy of PD-1 inhibitors but need further validation. Trial completion date: Jun 2027 --> Dec 2026 | Trial primary completion date: Jun 2027 --> Dec 2026
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation. (Pubmed Central) - Jun 21, 2024
Finally, we confirmed the synergistic effects of Lenvatinib and SAHA, or AZD5363 in primary liver cancer patient derived organoids. Collectively, these findings may enable the development of Lenvatinib combination therapies for HCC.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, IO biomarker: Thyroid carcinomas: the role of systemic therapies in internal medicine (Pubmed Central) - Jun 20, 2024
Where molecular targets are lacking, combination therapy with the MKI lenvatinib and immune checkpoint inhibition is highly effective...In summary, thyroid carcinomas are among the tumour entities for which molecularly targeted therapies can be used most frequently. The involvement of specialised centres is advisable.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase classification: A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 19, 2024
P1, N=30, Completed, Sponsor: Eisai Co., Ltd.
The involvement of specialised centres is advisable. Phase classification: P1b --> P1
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
P3 data, Journal, Metastases: Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. (Pubmed Central) - Jun 19, 2024
P3
Phase classification: P1b --> P1 In the phase 3 CLEAR trial, lenvatinib plus pembrolizumab (L + P) showed superior efficacy versus sunitinib in treatment-na
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, Journal, Metastases: A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial). (Pubmed Central) - Jun 19, 2024
The 1-year OS rate and median PFS were 75.9% and 7.2 months, respectively, with a median follow-up period of 9.3 months. The relatively high surgical resection rate seen in this study suggests the safety and feasibility of lenvatinib therapy followed by surgical resection for patients with oncologically or technically unresectable HCC.
- || Review, Journal, Metastases: Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy. (Pubmed Central) - Jun 19, 2024
This review highlights the efficacy of multikinase inhibitors and immune checkpoint inhibitors in monotherapy and combination therapy through the analysis of phase II, and III clinical trials, targeting the key molecular pathways involved in cellular signaling and immune response for the prospective treatment of advanced and unresectable HCC and discusses the upcoming combinations of immune checkpoint inhibitors-tyrosine kinase inhibitors and immune checkpoint inhibitors-vascular endothelial growth factor inhibitors. Finally, the hidden challenges with pharmacological therapy for HCC, feasible solutions for the future, and implications of possible presumptions to develop drugs for HCC treatment are reported.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Circ_0007386 Promotes the Progression of Hepatocellular Carcinoma Through the miR-507/ CCNT2 Axis. (Pubmed Central) - Jun 18, 2024
Circ_0007386 advanced HCC progression and lenvatinib resistance through the miR-507/ CCNT2 axis. Meanwhile, circ_0007386 served as a potential biomarker and therapeutic target in HCC patients.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date, Stroma, Metastases: LENVAGIST: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (clinicaltrials.gov) - Jun 18, 2024
P2, N=77, Completed, Sponsor: Centre Leon Berard
Meanwhile, circ_0007386 served as a potential biomarker and therapeutic target in HCC patients. Recruiting --> Completed | Trial completion date: Sep 2024 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Jan 2024
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Metastases: Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma (clinicaltrials.gov) - Jun 17, 2024
P=N/A, N=30, Not yet recruiting, Sponsor: Yunpeng Liu
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal: Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System. (Pubmed Central) - Jun 17, 2024
In brief, the nano-LVN delivery system has brought light to the war against cancer while at the same time improving the antitumor effect. More intelligent and multifunctional nanoparticles should be investigated and further converted into clinical applications in the future.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience. (Pubmed Central) - Jun 17, 2024
The combination of TACE-HAIC, PD-1 inhibitors and lenvatinib showed its benefit as a preoperative conversion therapy for nonmetastatic advanced HCC. In addition to imaging evaluation, significant reduction of 18F-FDG uptake and AFP can be used as predictors of successful conversion, especially for PVTT.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights. (Pubmed Central) - Jun 17, 2024
Despite the approval of immunotherapy in 2020, specifically the combination of atezolizumab and bevacizumab following the IMbrave150 trial, tyrosine kinase inhibitors remain an indispensable class of agents in the landscape of hepatocellular carcinoma treatment. This comprehensive review delves into various facets of lenvatinib utilization in hepatocellular carcinoma, shedding light on real-world data, addressing challenges, and providing insights into strategies to overcome these obstacles.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, PD(L)-1 Biomarker: Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with ESR1 gene amplification. (Pubmed Central) - Jun 17, 2024
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC (clinicaltrials.gov) - Jun 16, 2024
P=N/A, N=620, Active, not recruiting, Sponsor: Chen Xiaoping
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models (clinicaltrials.gov) - Jun 16, 2024
P1, N=30, Recruiting, Sponsor: Chen Xiaoping
- | limantrafin (CB-103) / Cellestia Biotech, Lenvima (lenvatinib) / Eisai, Merck (MSD), Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC (clinicaltrials.gov) - Jun 16, 2024
P1/2, N=34, Recruiting, Sponsor: Glenn J. Hanna
This comprehensive review delves into various facets of lenvatinib utilization in hepatocellular carcinoma, shedding light on real-world data, addressing challenges, and providing insights into strategies to overcome these obstacles. Trial primary completion date: Jun 2024 --> Jun 2025
- ||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date: IMbrave251: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (clinicaltrials.gov) - Jun 16, 2024
P3, N=554, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2024 --> Jun 2025 Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Jul 2025 | Trial primary completion date: Sep 2024 --> Jul 2025
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Combination therapy: Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta?analysis. (Pubmed Central) - Jun 14, 2024
The results of the present study indicated that, in the treatment of patients with uHCC, lenvatinib in combination with TACE showed a significantly improved efficacy when compared with sorafenib and TACE. Therefore, in the future, combination therapy of lenvatinib with TACE could be potentially prioritized over sorafenib with TACE for the treatment of patients with uHCC.
- | Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date: CCGLC-013: Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Jun 13, 2024
P2, N=36, Recruiting, Sponsor: Ze-yang Ding, MD
Therefore, in the future, combination therapy of lenvatinib with TACE could be potentially prioritized over sorafenib with TACE for the treatment of patients with uHCC. Initiation date: Jan 2024 --> Jun 2024
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Mismatch repair: Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer (clinicaltrials.gov) - Jun 12, 2024
P2, N=4, Active, not recruiting, Sponsor: Virginia Commonwealth University
Initiation date: Jan 2024 --> Jun 2024 Recruiting --> Active, not recruiting | N=100 --> 4 | Trial completion date: Sep 2035 --> Sep 2025 | Trial primary completion date: Sep 2025 --> Nov 2024
- ||| E7386 / Eisai, PRISM Pharma
Enrollment closed, Enrollment change: KEYNOTE-C83: A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors (clinicaltrials.gov) - Jun 12, 2024
P1/2, N=89, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting | N=100 --> 4 | Trial completion date: Sep 2035 --> Sep 2025 | Trial primary completion date: Sep 2025 --> Nov 2024 Recruiting --> Active, not recruiting | N=156 --> 89
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, Metastases: Metastatic glioblastoma to the lungs: a case report and literature review. (Pubmed Central) - Jun 12, 2024
This case contributes to the growing body of evidence for the role of genomic alterations in predictive risk in metastatic glioblastoma. There remains an unmet need for treatment of metastatic glioblastoma.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: GPX4 transcriptionally promotes liver cancer metastasis via GRHL3/PTEN/PI3K/AKT axis. (Pubmed Central) - Jun 11, 2024
As AKT is a downstream target of GPX4, we combined the AKT inhibitor, AKT-IN3, with lenvatinib to effectively inhibit HCC tumor cell metastasis. Overall, these results indicate that the GPX4/GRHL3/PTEN/PI3K/AKT axis controls HCC cell metastasis and lenvatinib combined with AKT-IN3 represents a potential therapeutic strategy for patients with metastatic HCC.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, IO biomarker, Metastases: The salvage lenvatinib-based regimen provides survival benefit in patients with refractory metastatic colorectal cancer. (Pubmed Central) - Jun 11, 2024
NGS analysis revealed that GNAS and KRAS alterations were associated with a worse treatment response and prolonged survival, respectively. In conclusion, a moderate-dose salvage lenvatinib-based regimen demonstrated promising clinical activity and tolerability in treating refractory mCRC.
- | Journal, Checkpoint inhibition: Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis. (Pubmed Central) - Jun 10, 2024
In conclusion, a moderate-dose salvage lenvatinib-based regimen demonstrated promising clinical activity and tolerability in treating refractory mCRC. TACE-TKI-ICI therapy contributed to better tumor control, PFS and OS than TKI-ICI therapy in unresectable HCC patients with first- or lower-order PVTT.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, P3 data, Journal, Tumor proportion score, Metastases: Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non?Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ?1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. (Pubmed Central) - Jun 8, 2024
P3
Lenvatinib plus pembrolizumab did not have a favorable benefit?risk profile versus placebo plus pembrolizumab. Pembrolizumab monotherapy remains an approved treatment option in many regions for first-line metastatic NSCLC with programmed cell death-ligand 1 tumor proportion score of at least 1% without EGFR/ALK alterations.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Observational data, Journal, Metastases: Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma. (Pubmed Central) - Jun 7, 2024
Pembrolizumab monotherapy remains an approved treatment option in many regions for first-line metastatic NSCLC with programmed cell death-ligand 1 tumor proportion score of at least 1% without EGFR/ALK alterations. No abstract available